Find out what's happening, new services, recommended reading, new books and more... brought to you by Alzheimer's Australia NSW Library & Information Service.
For more information contact the National Dementia Helpline on 1800 100 500.
Alzheimer disease (AD) is a fatal progressive disease and the most
common form of dementia without effective treatments. Previous studies support
that the disruption of endoplasmic reticulum Ca2+ through overactivation
of ryanodine receptors plays an important role in the pathogenesis of AD.
Normalization of intracellular Ca2+ homeostasis could be an
effective strategy for AD therapies. Dantrolene, an antagonist of ryanodine
receptors and an FDA-approved drug for clinical treatment of malignant
hyperthermia and muscle spasms, exhibits neuroprotective effects in multiple
models of neurodegenerative disorders. Recent preclinical studies consistently
support the therapeutic effects of dantrolene in various types of AD animal
models and were summarized in the current review.
Angina Pectoris Severity Among
Coronary Heart Disease Patients is Associated With Subsequent Cognitive
Background: The relationship between coronary heart disease (CHD) and
cognitive function is not completely elucidated. We examined the association between
severity of angina pectoris (AP) in mid-life and subsequent cognitive
impairment among CHD patients.
Conclusions: In people with preexisting CHD, severity of AP is
associated with late-life poorer cognitive performance, independent of other
vascular risk factors.
Cerebrovascular Diseases, and Cognitive Impairment in Chinese
Extracranial carotid artery disease has been shown to be related to
cognitive deficits. However, limited data are available on intracranial
stenosis (ICS) and cognitive impairment. We investigate the association between
ICS and cognitive impairment in Chinese.
Vascular Disease and Risk
Factors are Associated With Cognitive Decline in the Alzheimer Disease Spectrum
investigated the relationship between vascular disease and risk factors versus
cognitive decline cross-sectionally and longitudinally in normal older control,
mild cognitive impairment, and mild Alzheimer disease (AD) dementia subjects.
results suggest a significant association of increased vascular disease and
risk factors with cognitive impairment at baseline and over time in the AD
spectrum in a sample that was selected to have low vascular burden at baseline.
Cognitive Impairment Due to Alzheimer Disease is Less Likely Under the Age of
with amnestic mild cognitive impairment (aMCI) are considered to have a high
risk for Alzheimer dementia (AD). Even high positive predictive values,
however, cannot be guaranteed even by tests with high sensitivity and
specificity when disease prevalence is low. If we regard the clinical criteria
for aMCI as a test for predicting aMCI due to AD, the positive predictive value
of the criteria will be low by definition in young patients with aMCI (age
below 65 years) because of the low prevalence of AD in this age group.
Data for 8 Neuropsychological Tests in Older Blacks and Whites From the
Atherosclerosis Risk in Communities (ARIC) Study
assessment of cognitive impairment requires comparison of cognitive performance
in individuals to performance in a comparable healthy normative population. Few
prior studies have included a large number of black participants and few have
excluded participants from the normative sample with subclinical/latent
neurological disease or dementia. This study provides age, race, and education-specific
normative data for 8 cognitive tests derived from 320 black and 392 white
participants aged 61 to 82 years (mean 71 y) in the Atherosclerosis Risk in
Communities (ARIC) study without clinical or subclinical/latent neurological
Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia
A substantial part of elderly persons with dementia show rest-activity rhythm
disturbances. The rest-activity rhythm is important to study in people with
early-onset dementia (EOD) for rest-activity rhythm disturbances are predictive
of institutionalization, and caregivers of young patients suffer from high
EOD patients showed more variability in the rest-activity rhythm compared with
cognitively intact adults. The main predictor for rest-activity rhythm
disturbances was a low level of physical activity.
of Life in Alzheimer Disease: A Comparison of Patients’ and Caregivers’ Points
other chronic diseases, the Quality of Life (QoL) of patients affected by
Alzheimer Disease (AD) has not been well established, primarily because of the
difficulties stemming from the study of patients with cognitive disorders.
Because no cure is currently available for AD, the optimization of QoL represents
the best possible outcome attainable in all stages of disease, making QoL
Intervention in Semantic Dementia: Maintaining Words Over Time
with semantic dementia (SD) can improve their naming ability through cognitive
intervention, with good retention 1 month later. Beyond this time, improvements
often fade, yet no studies have investigated how to maintain performance.
in Cholesterol and Ganglioside GM1 Content of Lipid Rafts in Platelets From
Patients With Alzheimer Disease
of this study was to investigate the changes in the protein, cholesterol, and
ganglioside GM1 content of lipid rafts in platelets from patients with
Alzheimer disease (AD), and identify potential blood biomarkers of the disease.
Spousal Caregivers More Prevalent than Nonspousal Caregivers as Study Partners
in AD Dementia Clinical Trials?
Most Alzheimer disease (AD) caregivers are not spouses and yet most AD dementia
trials enroll spousal study partners. This study examines the association
between caregiver relationship to the patient and willingness to enroll in an
AD clinical trial and how caregiver burden and research attitudes modify
in Self-Reports of Health Services Use: Impact on Alzheimer Disease Clinical
Most Alzheimer disease clinical trials that compare the use of health services
rely on reports of caregivers. The goal of this study was to assess the
accuracy of self-reports among older adults with Alzheimer disease and their
caregiver proxy respondents. This issue is particularly relevant to Alzheimer
disease clinical trials because inaccuracy can lead both to loss of power and
increased bias in study outcomes.
A Case of
Globular Glial Tauopathy Presenting Clinically as Alzheimer Disease
Disease Masquerades as Dementia With Lewy Bodies
Alzheimers and Cortical Vision Impairment in a Woman With
Valosin-containing Protein Disease Associated With 2 APOE [Latin Small
Letter Open E]4/APOE [Latin Small Letter Open E]4 Genotype
Amyloid Imaging in Logopenic Progressive Aphasia
Cytokines and the Clinical Features of Dementia With Lewy Bodies